QUEBEC CITY, Feb. 20 /PRNewswire-FirstCall/ - Atrium Biotechnologies Inc. today announced that its quarterly conference call and webcast have been scheduled for Tuesday February 27, 2007 at 10 a.m. Eastern time. The call will follow the press release of Atrium’s 2006 fourth quarter and full year results earlier the same day. Participants may access the call by using the following numbers: 416-644-3414, 514-807-8791 or 800-732-9307 or via the Company’s website at www.atrium-bio.com in the “Investors” section.
A replay of the webcast will also be available on our website www.atrium-bio.com in the “Investors” section for a period of 30 days.
About Atrium
Atrium Biotechnologies Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 560 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at www.atrium-bio.com.
Cautionary Note and Forward-Looking Statements
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company’s quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.
ATRIUM BIOTECHNOLOGIES INC.
CONTACT: Investor Relations: John Dempsey, Vice President, Finance andChief Financial Officer, (418) 652-1116 ext. 287, jdempsey@atrium-bio.com;Media Relations: Frederic Tremblay, HKDP, (514) 395-0375 ext. 234,ftremblay@hkdp.qc.ca; Source: Atrium Biotechnologies Inc.
